Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-651-7 | CAS number: 692-49-9
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Male and female rats were exposed to the substance via inhalation and toxicokinetics parameters including absorption, distribution, metabolism, and excretion were evaluated. These parameters subsequently provided information on the potential for accumulation of the test substance in the tissues/organs that were evaluated. The results indicated that test substance is systemically absorbed via the inhalation route of exposure and no indication of accumulation potential was identified. The absorption of the test substance was rapid with steady-state in whole blood occurring by 2 hours during a 6-hour exposure. The pharmacokinetic behavior of the substance in blood was similar between males and females following various exposure concentrations and durations with whole blood elimination half-lives ranging from 0.19-1.5 hours. The test substance was distributed throughout the tissues within 30 minutes after a single 6-hour exposure to 10000 ppm of the substance and there was no indication of accumulation potential. Excretion was substantially complete by 18 hours post exposure. The pattern of distribution and excretion was similar across sex and dose. The relatively small amounts of parent test substance that was detected in the urine and faeces were likely due to volatility during collection. Elimination via exhalation could not be determined under the conditions of this study. Metabolism of the absorbed dose was extensive and was characterized by identified components in blood, tissues, bile, urine, and faeces. The primary biotransformation steps for the test substance appear to be either oxidation or direct conjugation with glutathione. Additional secondary metabolism resulted in phase I and phase II metabolites including oxidation to a ketone, formation of a second glutathione conjugate, or further hydrolysis to dihydroxyl-test substance and glucuronidation. The glutathione conjugates were degraded to cysteine conjugates and N-acetylated cysteine conjugates. The metabolic profile appears to be qualitatively similar between male and female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
